News
Zacks Investment Research on MSN2h
SRPT Down After Third Death in Muscular Dystrophy Gene Therapy Program
Shares of Sarepta Therapeutics SRPT nosedived 35.9% on Friday following the death of a patient dosed with one of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback